These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15709160)

  • 21. The ongoing evolution of dendritic cell therapy.
    Sokoloff MH; Vogelzang N
    Cancer; 1999 Dec; 86(12):2593-6. PubMed ID: 10594853
    [No Abstract]   [Full Text] [Related]  

  • 22. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania.
    León B; López-Bravo M; Ardavín C
    Immunity; 2007 Apr; 26(4):519-31. PubMed ID: 17412618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of tumor-specific T cells by dendritic cells expressing the NY-ESO-1 antigen after transfection with the cationic lipophosphoramide KLN5.
    Le Gallo M; Toutirais O; Montier T; Cabillic F; Bouet F; Delépine P; Lehn P; Jotereau F; Catros V
    J Gene Med; 2008 Jun; 10(6):628-36. PubMed ID: 18338820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dendritic cells and cancer therapy].
    Baggers J
    Ugeskr Laeger; 2000 Oct; 162(44):5940-1. PubMed ID: 11094562
    [No Abstract]   [Full Text] [Related]  

  • 25. Dendritic cells and pluripotency: unlikely allies in the pursuit of immunotherapy.
    Fairchild PJ; Leishman A; Sachamitr P; Telfer C; Hackett S; Davies TJ
    Regen Med; 2015; 10(3):275-86. PubMed ID: 25933237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro.
    Yano Y; Ueda Y; Itoh T; Fuji N; Okugawa K; Naito K; Imura K; Kohara J; Hayashi T; Nakane K; Matsuura Y; Kawai K; Yamagishi H
    Oncol Rep; 2006 Jul; 16(1):147-52. PubMed ID: 16786138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical-scale generation of strongly CD83-expressing dendritic cells using extracorporeal photopheresis.
    Bredberg A; Jonsson S; Lindblom A; Björk P
    Photodermatol Photoimmunol Photomed; 2007 Aug; 23(4):113-9. PubMed ID: 17598863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monocyte enriched apheresis for preparation of dendritic cells (DC) to be used in cellular therapy.
    Svensson A; Adamson L; Pisa P; Petersson M; Hansson M
    Transfus Apher Sci; 2005 Oct; 33(2):165-73. PubMed ID: 16129662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacterial product cantastim derived from Pseudomonas aeruginosa induces migration and maturation of dendritic cells.
    Caraş I; Tucureanu C; Lerescu L; Sălăgeanu A
    Roum Arch Microbiol Immunol; 2007; 66(1-2):5-9. PubMed ID: 18928056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monocyte-derived dendritic cells.
    León B; López-Bravo M; Ardavín C
    Semin Immunol; 2005 Aug; 17(4):313-8. PubMed ID: 15955712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells.
    Nencioni A; Garuti A; Schwarzenberg K; Cirmena G; Dal Bello G; Rocco I; Barbieri E; Brossart P; Patrone F; Ballestrero A
    Eur J Immunol; 2006 Mar; 36(3):681-9. PubMed ID: 16479541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.
    Delcayre A; Shu H; Le Pecq JB
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):537-47. PubMed ID: 16001959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of human plasma proteins on maturation of monocyte-derived dendritic cells.
    Tobiásová-Czetoová Z; Palmborg A; Lundqvist A; Karlsson G; Adamson L; Bartůnková J; Masucci G; Pisa P
    Immunol Lett; 2005 Sep; 100(2):113-9. PubMed ID: 16154491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anti-tumor effect of human monocyte-derived dendritic cells loaded with HSV-TK/GCV induced dying cells.
    Xing W; Wu S; Yuan X; Chen Q; Shen X; He F; Bian J; Lei P; Zhu H; Wang S; Shen G
    Cell Immunol; 2009; 254(2):135-41. PubMed ID: 18834973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential applications for plasmacytoid dendritic cells in cancer immunotherapy.
    Tel J; de Vries IJ
    Immunotherapy; 2012 Oct; 4(10):979-82. PubMed ID: 23148748
    [No Abstract]   [Full Text] [Related]  

  • 37. Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo.
    Biglari A; Southgate TD; Fairbairn LJ; Gilham DE
    Gene Ther; 2006 Apr; 13(7):602-10. PubMed ID: 16397508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients.
    Lee JJ; Choi BH; Kang HK; Kim SK; Nam JH; Yang DH; Kim YK; Kim HJ; Chung IJ
    Leuk Res; 2008 Nov; 32(11):1653-60. PubMed ID: 18501426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
    Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
    Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment.
    Matsumura N; Mandai M; Hamanishi J; Yamaguchi K; Fukuhara K; Yagi H; Higuchi T; Takakura K; Fujii S
    Oncol Rep; 2008 Feb; 19(2):505-15. PubMed ID: 18202801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.